Sign in
Taking peoplePhase 2

Surgery to remove lymph nodes in testicular seminoma with limited spread

Tests lymph node removal surgery in men with testicular seminoma spread to nearby nodes.

Key facts

Who runs it
Western University, Canada
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
17 Jul 2025
Expected to end
1 Jun 2030
Type of study
Interventional
Treatments tested
  • Retroperitoneal Lymph Node Dissection
Record updated
20 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult men with pure testicular seminoma that has spread to a few lymph nodes at the back of the belly. They will have surgery to remove these lymph nodes.

Age
Over 18 years
Sex
Male
Disease stage
Stage II seminoma, either at first diagnosis or as a return of stage I disease during follow-up. No more than 2 enlarged lymph nodes at the back of the belly, each no more than 3cm (1.2 in). Scans must be done within 8 weeks of the surgery.
Earlier treatment
Must have had surgery to remove the testicle (radical orchiectomy), showing pure seminoma.
Biomarker or test result
Blood tumour markers AFP, HCG and LDH must all be normal within 2 weeks of the planned surgery. AFP must never have been above 20, before or after testicle removal.

Main reasons for not taking part

  • Any health problem the surgeon thinks makes the lymph node surgery too risky
  • Any non-seminoma part in the removed testicle tissue
  • AFP above 20 at any time
  • Not able to have the planned surgery on both sides of the lymph node area

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult patients (>18 years) with pure seminoma on radical orchiectomy specimen
  • Initial CS I presentation with subsequent retroperitoneal relapse on surveillance, or de novo CS II at presentation
  • Axial imaging of lymphadenopathy within 8 weeks of the date of RPLND; No more than 2 enlarged retroperitoneal lymph nodes, each no more than 3cm in the primary landing zones; Suitable for proposed bilateral RPLND template
  • Serum tumour markers (alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH)) must all be within normal limits within 2 weeks of planned RPLND

Who cannot take part

  • Any condition deemed by the treating surgeon to pose an unacceptable risk for retroperitoneal lymph node dissection
  • Any non-seminoma component on the orchiectomy specimen
  • AFP >20 at any time point, pre- or post-orchiectomy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%).

Read full original descriptionShow less

For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients

The group in the trial

  • CS IIA/IIB SeminomaOther group

    Patients with relapsed CS I or de novo CS IIA/B with \<3cm lymph node in the retroperitoneal lymph node.

    Treatment: Retroperitoneal Lymph Node Dissection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Single-arm Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Plain-language title
Surgery to remove lymph nodes in testicular seminoma with limited spreadGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
20 July 2025